Appropriate use of tocilizumab in COVID-19 infection
Authors:
- Şiran KeskeŞKŞiran Keske
- Pelin İrKörenPIPelin İrKören
- İrFan ÇelebiIÇİrFan Çelebi
Open Access
- 1 October 2020
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 338-343
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic virusesEmerging Microbes & Infections, 2020
- Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsMediators of Inflammation, 2017
- Cytokine storm and sepsis disease pathogenesisSeminars in Immunopathology, 2017
- IL-6 as a keystone cytokine in health and diseaseNature Immunology, 2015
- A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategySeminars in Immunology, 2014